Biopharma firm Morphic debuts IPO
Waltham, Massachusetts-based Morphic, a biopharmaceutical company, has raised about $90 million for its IPO after pricing its 6 million shares at $15 per share. The stock began trading June 27, 2019 on the NASDAQ under the ticker symbol "MORF." Jefferies LLC, Cowen and Company, LLC, BMO Capital Markets Corp. and Wells Fargo Securities LLC are the underwriters. Morphic's pre-IPO backers included Omega Funds, Novo Holdings, Invus and EcoR1 Capital.
27 June 2019•3 mins read
